Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Relapse in stage I(E) diffuse large B-cell lymphoma
Published in: HEMATOLOGICAL ONCOLOGY
Access to document
10.1002/hon.2487
document
Despite a general favourable outcome in limited stage diffuse large B-cell lymphoma (DLBCL), relapses occur in about 10 to 20% of patients. Prognostic models only partially identify patients at risk for relapse. Moreover, it is not known whether the outcome after such a relapse is similar to the outcome after relapse in advanced stages. From January 2004 through December 2012, all newly diagnosed patients with stage I(E) DLBCL were retrospectively analysed from 2 clinical databases to investigate the relapse pattern and outcome in relation to initial treatment and...
Marcel Nijland, Karin Boslooper, Gustaaf van Imhoff, Robbie Kibbelaar, Peter Joosten, Huib Storm, Eric N van Roon, Arjan Diepstra, Hanneke C Kluin-Nelemans, Mels Hoogendoorn
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens
Published in: Annals of Hematology
Access to document
10.1007/s00277-017-3167-7
document
Burkitt lymphoma is an aggressive B cell malignancy accounting for 1-2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy is effective but associated with considerable toxicity. In this observational study, we compared real-world efficacy, toxicity, and costs of four frequently employed treatment strategies for Burkitt lymphoma: the Lymphome Malins B (LMB), the Berlin-Frankfurt-Munster (BFM), the HOVON, and the CODOX-M/IVAC regimens. We collected data from 147 adult patients treated in eight referral centers. Following central Burkitt lymphoma, resulting in the following treatment groups: LMB 36 patients, BFM 19...
L. E. M. Oosten, M. E. D. Chamuleau, F. W. Thielen, L. C. de Wreede, C. Siemes, J. K. Doorduijn, O. S. Smeekes, M. J. Kersten, L. Hardi, J. W. Baars, A. M. P. Demandt, W. B. C. Stevens, M. Nijland, G. W. van Imhoff, R. Brouwer, C. A. Uyl-de Groot, P. M. Kluin, D. de Jong, H. Veelken
Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review
Filipe Montes de Jesus, Thomas Kwee, Marcel Nijland, Xaver-Ulrich Kahle, Geert Huls, Rudi Dierckx, Tom van Meerten, Olivier Gheysens, D Dierickx, Walter Noordzij, Andor W.J.M. Glaudemans
High Prevalence of Oncogenic MYD88 and CD79B Mutations in Intravascular Large B-Cell Lymphoma: Implication for Therapy with Bruton’s Kinase Inhibitors?
Sebastiaan Somers, Patty Jansen, Hendrik Veelken, Maarten Vermeer, Willem Kraan, Anne-Roos Schrader, Ward Posthuma, Marcel Nijland, Arjan Diepstra, Marie Jose Kersten, Steven Pals, Arjen Cleven, Joost Vermaat
MYC expression and translocation analyses in low-grade and transformed follicular lymphoma
Published in: Histopathology
Access to document
10.1111/his.13316
document
AimsLow-grade follicular lymphoma (FL) (grade 1/2, FL1/2) has an annual risk of transformation of approximate to 3%, which is associated with aberrations in CDKN2A/B, TP53, and MYC. As in diffuse large B-cell lymphoma, high MYC expression in transformed FL (tFL) might predict a MYC breakpoint. Methods and resultsWe quantified MYC expression by immunohistochemistry and digital analysis in 41 paired biopsies from 20 patients with FL1/2 with subsequent transformation and in four isolated biopsies of tFL. As controls, 28 biopsies of FL1/2 without transformation (median follow-up of 105 months)...
Sietse M. Aukema, Roel van Pel, Inga Nagel, Susanne Bens, Reiner Siebert, Stefano Rosati, Eva van den Berg, Anneke G. Bosga-Bouwer, Robby E. Kibbelaar, Mels Hoogendoorn, Gustaaf W. van Imhoff, Hanneke C. Kluin-Nelemans, Philip M. Kluin, Marcel Nijland